Neuroendocrine carcinoma of the prostate (review of the literature)
- 作者: Abbasova D.1, Polikarpova S.1, Kozlov N.2, Baranova M.3, Kovalenko I.2, Ignatova E.2
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- Blokhin National Medical Research Center of Oncology
- Russian Medical Academy of Continuous Professional Education
- 期: 卷 21, 编号 3 (2019)
- 页面: 52-55
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33532
- DOI: https://doi.org/10.26442/18151434.2019.3.190673
- ID: 33532
如何引用文章
全文:
详细
作者简介
Daria Abbasova
Sechenov First Moscow State Medical University (Sechenov University)
Email: dariaabbasova@yandex.ru
Graduate Student, S Moscow, Russia
Svetlana Polikarpova
Sechenov First Moscow State Medical University (Sechenov University)
Email: svetac@mail.ru
д-р мед. наук, проф. каф. онкологии лечебного фак-та Moscow, Russia
Nikolai Kozlov
Blokhin National Medical Research Center of OncologyCand. Sci. (Med.) Moscow, Russia
Madina Baranova
Russian Medical Academy of Continuous Professional Education
Email: protokosha@yandex.ru
Cand. Sci. (Med.) Moscow, Russia
Irina Kovalenko
Blokhin National Medical Research Center of OncologyCand. Sci. (Med.) Moscow, Russia
Elena Ignatova
Blokhin National Medical Research Center of OncologyCand. Sci. (Med.) Moscow, Russia
参考
- Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carcinoma of the bladder and prostate. Urology 1995; 46 (5): 617-30.
- Cohen R.J, Glezerson G, Taylor L.F, Grundle H.A, Naude J.H. The neuroendocrine cell population of the human prostate gland. J Urol 1993; 150: 365-8.
- Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-48.
- Epstein J.I, Amin M.B, Beltran H et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 2014; 38 (6): 756-67.
- Komiya A, Suzuki H, Imamoto T et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16: 37-44.
- Mucci N.R, Akdas G, Manely S et al. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000; 31: 406-14.
- Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005; 47: 147-55.
- The WHO Classification of Tumours of the Urinary System and Male Genital Organs presented in this book reflects the views of a Working Group that convened for an Editorial and Consensus and Editorial Meeting at the University Hospital Zürich, Zürich, 11-13 March 2015.
- Freschi M, Colombo R, Naspro R et al. Primary and pure neuroendocrine tumor of the prostate. Eur Urol 2004; 45: 166-9.
- Giordano S, Tolonen T, Tolonen T et al. A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Int Urol Nephrol 2010; 42: 683-7.
- Goulet-Salmon B, Berthe E, Franc S et al. Prostatic neuroendocrine tumor in multiple endocrineneoplasia type 2B. J Endocrinol Invest 2004; 27: 570-3.
- Whelan T, Gatfield C.T, Robertson S et al. Primary carcinoid of the prostate in conjunction withmultiple endocrine neoplasia IIb in a child. J Urol 1995; 153: 1080-2.
- Abrahamsson P.A, Cockett A.T, di Sant’Agnese P.A. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate (Suppl.) 1998; 8: 37-42.
- Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001; 12 (Suppl. 2): S141-144.
- Hirano D, Okada Y, Minei S et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-92. Discussion 592.
- Berruti A, Mosca A, Porpiglia F et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007; 178: 838-43. Quiz 1129.
- Casella R, Bubendorf L, Sauter G et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 1998; 160: 406-10.
- Weinstein M.H, Partin A.W, Veltri R.W, Epstein J.I. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683-7.
- Bubendorf L, Sauter G, Moch H et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437-41.
- Noordzij M.A, van der Kwast T.H, van Steenbrugge G.J et al. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995; 62: 252-8.
- Segawa N, Mori I, Utsunomiya H et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-9.
- Speights V.O Jr, Cohen M.K, Riggs M.W et al. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples. Br J Urol 1997; 80: 281-6.
- Bollito E, Berruti A, Bellina M et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001; 12 (Suppl. 2): S159-164.
- Cohen R.J, Glezerson G, Haffejee Z. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Br J Urol 1991; 68: 258-62.
- Cheville J.C, Tindall D, Boelter C et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002; 95: 1028-36.
- Jiborn T, Bjartell A, Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology 1998; 51: 585-9.
- Krijnen J.L, Bogdanowicz J.F, Seldenrijk CA et al. The prognostic value of neuroendocrine differentiation in ad enocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158: 171-4.
- Tarle M, Ahel M.Z, Kovacic K. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Anticancer Res 2002; 22: 2525-9.
- Wenk R.E, Bhagavan B.S, Levy R et al. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia. Cancer 1977; 40 (2): 773-8.
- Marcus D.M, Goodman M, Jani A.B et al. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012; 15: 283-8.
- Têtu B, Ro J.Y, Ayala A.G et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 1987; 59 (10): 1803-9.
- Wang W, Epstein J.I. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71.
- Yao J.L, Madeb R, Bourne P et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006; 30: 705-12.
- Agoff S.N, Lamps L.W, Philip A.T et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000; 13: 238-42.
- Tomlins S.A, Rhodes D.R, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
- Lotan T.L, Gupta N.S, Wang W et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820-8.
- Han B, Mehra R, Lonigro R.J et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083-93.
- Guo C.C, Dancer J.Y, Wang Y et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 2011; 42: 11-7.
- Williamson S.R, Zhang S, Yao J.L et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod Pathol 2011; 24: 1120-7.
- Scheble V.J, Braun M, Wilbertz T et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 2010; 56: 937-43.
- Schelling L.A, Williamson S.R, Zhang S et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013.
- Slater D. Carcinoid tumour of the prostate associated with inappropriate ACTH secretion. Br J Urol 1985; 57: 591-2.
- Deorah S, Rao M.B, Raman R et al. Survival of patients with small cell carcinoma of the prostate during 1973-2003: A populationbased study. BJU Int 2012; 109: 824-30.
- Amato R.J, Logothetis C.J, Hallinan R et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147: 935-7.
- Rubenstein J.H, Katin M.J, Mangano M.M et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 1997; 20: 376-80.
- Aparicio A.M, Harzstark A.L, Corn P.G et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621-30.
- Papandreou C.N, Daliani D.D, Thall P.F et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20: 3072-80.
- Evans A.J, Humphrey P.A, Belani J et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006; 30: 684-93.